• Hareton Teixeira Vechi, Lucas Rodrigues Maia, and Manoella do Monte Alves.
• Universidade Federal do Rio Grande do Norte, Escola Multicampi de Ciências Médicas, Departamento de Medicina, Caicó, Rio Grande do Norte, Brazil.
• Rev. Inst. Med. Trop. Sao Paulo. 2020 Sep 4; 62: e63.

AbstractIn late 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as the cause of a cluster of pneumonia cases in China, and the corresponding disease was designated as Coronavirus Disease 2019 (COVID-19), spreading quickly around the world resulting in a pandemic. COVID-19 is associated with a set of coagulation abnormalities that increase the risk of thromboembolic events, especially in patients with severe/critical disease. We describe a series of five cases of mild COVID-19, treated in an outpatient clinic, which, after an apparent clinical improvement, developed acute pulmonary embolism (APE) between the third and the fourth week after the onset of symptoms, when they are mostly related to acute illness disappearance. Thromboembolic events are also a potential complication of mild COVID-19 and can manifest later in the disease course. This finding raises discussion about the prevention of thromboembolic events in selected group of patients with mild COVID-19.

18 keywords...

hide…